• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional treatment and medications do not work for many patients suffering from depression. A customized treatment may be the answer.

Cue is an intervention platform that converts passively acquired sensor data from smartphones into personalized micro-interventions for improving mental health. We analysed the best-fit personalized ML models for each subject using Shapley values to identify their predictors of feature and reveal distinct characteristics that can be used to predict changes in mood with time.

Predictors of Mood

Depression is the leading cause of mental illness around the world.1 Yet the majority of people affected receive treatment. To improve outcomes, healthcare professionals must be able to recognize and treat patients who have the highest probability of responding to certain treatments.

A customized depression treatment plan can aid. Utilizing sensors for mobile phones as well as an artificial intelligence voice assistant and other digital tools researchers at the University of Illinois Chicago (UIC) are developing new methods to predict which patients will benefit from which treatments. Two grants worth more than $10 million will be used to discover biological and behavioral factors that predict response.

The majority of research done to date has focused on sociodemographic and clinical characteristics. These include demographics like age, gender, and education, and clinical characteristics like symptom severity, comorbidities and biological markers.

While many of these factors can be predicted by the information available in medical records, very few studies have utilized longitudinal data to explore predictors of mood in individuals. Many studies do not take into account the fact that moods can be very different between individuals. Therefore, it is crucial to develop methods which permit the analysis and measurement of personal differences between mood predictors treatments, mood predictors, etc.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team is able to develop algorithms to identify patterns of behavior and emotions that are unique to each person.

The team also created a machine-learning algorithm that can identify dynamic predictors of each person's mood for depression. The algorithm combines the individual differences to create an individual "digital genotype" for each participant.

This digital phenotype was found to be associated with CAT DI scores, a psychometrically validated scale for assessing severity of symptom. However the correlation was tinny (Pearson's r = 0.08, the BH-adjusted p-value was 3.55 x 10-03) and varied widely across individuals.

Predictors of Symptoms

Depression is the most common reason for disability across the world, but it is often untreated and misdiagnosed. In addition, a lack of effective treatments and stigmatization associated with depression disorders hinder many individuals from seeking help.

To help with personalized treatment, it is important to determine the predictors of symptoms. However, current prediction methods are based on the clinical interview, which is not reliable and only detects a tiny variety of characteristics associated with depression and treatment.2

Machine learning can improve the accuracy of the diagnosis and treatment of depression by combining continuous digital behavioral patterns gathered from sensors on smartphones along with a verified mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). Digital phenotypes permit continuous, high-resolution measurements. They also capture a wide variety of unique behaviors and activity patterns that are difficult to capture using interviews.

The study comprised University of California Los Angeles students with mild to severe depression symptoms who were enrolled in the Screening and Treatment for Anxiety and Depression program29 that was developed as part of the UCLA Depression Grand Challenge. Participants were routed to online assistance or in-person clinics in accordance with their severity of depression. Participants who scored a high on the CAT DI of 35 65 were allocated online support via the help of a peer coach. those with a score of 75 were sent to clinics in-person for psychotherapy.

Participants were asked a series questions at the beginning of the study about their demographics and psychosocial traits. These included age, sex and education, as well as work and financial status; if they were divorced, married, or single; current suicidal ideas, intent, or attempts; and the frequency at the frequency they consumed alcohol. The CAT-DI was used for assessing the severity of depression-related symptoms on a scale ranging from zero to 100. The CAT-DI test was conducted every two weeks for participants who received online support, and weekly for those who received in-person care.

Predictors of Treatment Response

Research is focusing on personalization of depression treatment. Many studies are aimed at identifying predictors, which will aid clinicians in identifying the most effective drugs to treat each individual. In particular, pharmacogenetics identifies genetic variants that determine the way that the body processes antidepressants. This lets doctors select the medication that are likely to be the most effective for each patient, while minimizing the amount of time and effort required for trials and errors, while eliminating any adverse effects.

Another promising approach is building models of prediction using a variety of data sources, combining data from clinical studies and neural imaging data. These models can be used to determine the variables that are most predictive of a specific outcome, such as whether a drug will improve symptoms or mood. These models can be used to predict the patient's response to a treatment, which will help doctors maximize the effectiveness.

A new generation of studies utilizes machine learning techniques such as supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to blend the effects of several variables and improve the accuracy of predictive. These models have been proven to be effective in predicting the outcome of treatment like the response to antidepressants. These methods are becoming popular in psychiatry, and it is likely that they will become the norm for future clinical practice.

In addition to prediction models based on ML The study of the underlying mechanisms of depression continues. Recent findings suggest that the disorder is associated with neurodegeneration in particular circuits. This suggests that individual depression treatment will be built around targeted treatments that target these neural circuits to restore normal function.

Internet-delivered interventions can be an effective method to accomplish this. They can offer a more tailored and individualized experience for patients. One study found that an internet-based program helped improve symptoms and led to a better quality life for MDD patients. In addition, a controlled randomized study of a customized approach to treating depression showed an improvement in symptoms and fewer adverse effects in a large proportion of participants.

Predictors of adverse effects

A major challenge in personalized depression treatment is predicting which antidepressant medications will cause minimal or no side effects. Many patients are prescribed various drugs before they find a non drug treatment for anxiety and depression that is both effective and well-tolerated. Pharmacogenetics offers a fascinating new avenue for a more efficient and targeted method of selecting antidepressant therapies.

Many predictors can be used to determine the best antidepressant to prescribe, including gene variants, patient phenotypes (e.g. sexual orientation, gender or ethnicity) and the presence of comorbidities. However finding the most reliable and valid predictors for a particular treatment is likely to require controlled, randomized trials with much larger samples than those typically enrolled in clinical trials. This is because the identifying of moderators or interaction effects may be much more difficult in trials that only consider a single episode of treatment per patient instead of multiple episodes of treatment over a period of time.

In addition to that, predicting a patient's reaction will likely require information about the comorbidities, symptoms profiles and the patient's subjective perception of the effectiveness and tolerability. Currently, only a few easily identifiable sociodemographic variables and clinical variables seem to be reliable in predicting the response to MDD. These include gender, age, race/ethnicity, SES, BMI and the presence of alexithymia.

The application of pharmacogenetics in treatment for depression is in its infancy and there are many obstacles to overcome. first line treatment for anxiety and depression is a thorough understanding of the underlying genetic mechanisms is needed and a clear definition of what is a reliable predictor of treatment response. In addition, ethical concerns like privacy and the responsible use of personal genetic information, must be carefully considered. In the long-term pharmacogenetics can be a way to lessen the stigma associated with mental health care and improve the outcomes of those suffering with depression. But, like any approach to psychiatry careful consideration and implementation is necessary. For now, the best option is to provide patients with various effective medications for depression and encourage them to talk freely with their doctors about their experiences and concerns.